Gilead Up As Remdesivir Shows Promise In Treating Coronavirus
Zacks Investment Research | Mar 16, 2020 06:30AM ET
Shares of Gilead Sciences (NASDAQ:GILD) gained 3.76% on Mar 13 as, per reports, its experimental candidate, remdesivir, showed promising results in 14 Americans hospitalized in Japan for the treatment of COVID-19.
In fact, shares have gained 4.8% in the past month against the industry ’s decline of 12.9%. While the broader market is seeing a massive decline amid global selloffs, Gilead’s shares have gained as it is now the frontrunner in the race of companies developing treatments for COVID-19.
Last week, The World Health Organization (WHO) declared the outbreak of COVID-19 as a pandemic, given the alarming levels of spread and severity.
Currently, there are no FDA-approved treatments for the same. While big companies like AbbVie (NYSE:ABBV) are working with health authorities to evaluate the efficacy of drugs in hand, developing a cure for this disease has become a race against time. Given the widespread outbreak, the spotlight is particularly on companies, which are developing treatments/vaccines for the same.
The company pioneering the race is Gilead, which has initiated two phase III studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19. These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily across Asian countries. The studies will assess two dosing durations of the candidate, administered intravenously. Reportedly, remdesivir is already being used in the United States for the treatment of the disease under federal rules that allow the use of unapproved drugs on compassionate grounds.
Remdesivir was previously under testing for Ebola virus. As the candidate has shown promising results in the infected patients, investors are banking on Gilead for being the first company to come up with a treatment for this deadly disease. Per reports, the 14 Americans who were aboard the Diamond Princess cruise ship and got infected with COVID-19 were given remdesivir intravenously once a day for 10 days. More than half of them have recovered post the treatment.
Apart from Gilead Sciences, smaller biotechs like Vir Biotechnology, Inc. (NASDAQ:VIR) and Moderna (NASDAQ:MRNA) have grabbed the spotlight as they strive to develop treatments to fight this pandemic. Vir Biotechnology recently signed a letter of intent with biotech bigwig, Biogen Inc. (NASDAQ:BIIB) , for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of COVID-19.
Get The News You Want
Gilead currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.